Investigación sobre Metabólico
Agonistas de los receptores GLP-1 y GIP para investigación metabólica. A continuación se encuentra la literatura publicada para cada compuesto en esta área — 206 estudios en total, 103 de ellos publicados desde 2023, cada uno vinculado a su registro fuente.
- MetabólicoSolo preclínico
5-Amino-1MQ
5-Amino-1MQ (5-amino-1-metilquinolinio) es un inhibidor de molécula pequeña permeable a la membrana celular de la nicotinamida N-metiltransferasa (NNMT), la enzima que metila la nicotinamida y con ello consume S-adenosilmetionina y desvía la nicotinamida de la ruta de recuperación de NAD+. El interés en el objetivo siguió a un informe de Nature de 2014 en el que el silenciamiento antisentido de NNMT en tejido adiposo e hígado protegió a ratones contra la obesidad inducida por dieta. Trabajos posteriores caracterizaron 5-amino-1MQ e inhibidores de quinolinio relacionados en roedores obesos por dieta, músculo esquelético envejecido, modelos de sarcopenia y enfermedad arterial periférica, junto con estudios de química medicinal y mecanismo de inhibición. La base de evidencia publicada es enteramente preclínica; ningún ensayo clínico en humanos de 5-amino-1MQ ha sido reportado en la literatura revisada por pares.
- Estudios
- 15
- Desde 2023
- 8
- Más reciente
- 2026
- MetabólicoClínico temprano
AOD-9604
AOD-9604 es un hexadecapéptido sintético correspondiente al dominio lipolítico C-terminal de la hormona de crecimiento humana (Tyr-hGH 177-191, comúnmente escrito como fragmento hGH 176-191). El trabajo preclínico publicado entre 1993 y 2001 caracterizó los efectos del fragmento sobre la lipólisis, la lipogénesis y la oxidación de grasas en modelos de roedores e informó que estos efectos se produjeron sin interacción medible con el receptor de hGH o elevación de IGF-1. El compuesto posteriormente entró en ensayos clínicos de obesidad en humanos, cuyos datos agrupados de seguridad y tolerabilidad se publicaron en 2013, y datos no clínicos de genotoxicidad y toxicología crónica que respaldaban una posición como ingrediente alimentario se publicaron en 2014; ningún ensayo de eficacia ha aparecido como informe independiente revisado por pares. La literatura posterior está dominada por química analítica antidopaje, un estudio de osteoartritis intraarticular en conejos y revisiones narrativas de péptidos en ortopedia y medicina deportiva.
- Estudios
- 17
- Desde 2023
- 4
- Más reciente
- 2026
- MetabólicoFármaco aprobado
Lemon Bottle
Injectable lipolysis has been studied mainly as deoxycholic acid (ATX-101), a synthetic bile salt approved for submental fat reduction on the basis of two phase 3 randomised trials (REFINE-1 and REFINE-2), and as compounded phosphatidylcholine/sodium deoxycholate formulations, which were never approved for this use. Preclinical work indicated that the deoxycholate component, acting as a detergent that disrupts cell membranes, was the principal adipocytolytic agent rather than phosphatidylcholine. The reported adverse-event profile includes injection-site swelling and induration, marginal mandibular nerve paresis, skin ulceration and necrosis, fibrosis, and post-procedural infection, with animal data documenting demyelinating nerve injury after intrafascicular exposure. The branded product marketed as 'Lemon Bottle' was not identified in any peer-reviewed clinical or mechanistic study, so the evidence described here relates to deoxycholic acid and phosphatidylcholine/deoxycholate rather than to that specific formulation.
- Estudios
- 39
- Desde 2023
- 15
- Más reciente
- 2026
- MetabólicoClínico
Lipo-C Fat Blaster
Lipo-C refers to a compounded injectable mixture whose typical constituents are methionine, inositol, choline, L-carnitine and vitamin B12. The published literature addresses these substances individually rather than as a combined injection, and the bulk of that evidence comes from oral supplementation trials and observational nutrition studies. Component-level findings span body-composition meta-analyses for L-carnitine, hepatic steatosis work for choline, insulin-sensitivity and gestational diabetes meta-analyses for myo-inositol, small human studies of dietary methionine restriction, and status and route-of-administration analyses for vitamin B12. Evidence generated for one component under one route and dose does not transfer to a multi-ingredient injectable preparation.
- Estudios
- 35
- Desde 2023
- 13
- Más reciente
- 2026
- MetabólicoClínico
Retatrutide
Retatrutide (LY3437943) is an investigational single-peptide triple agonist of the GIP, GLP-1 and glucagon receptors, first described in preclinical rodent pharmacology and phase 1 studies in 2022 and subsequently in phase 2 randomised trials in obesity, type 2 diabetes and metabolic dysfunction-associated steatotic liver disease. Phase 2 reports documented dose-dependent reductions in body weight, HbA1c and liver fat content, alongside predominantly gastrointestinal adverse events. A registrational phase 3 programme (TRIUMPH) and a separate TRANSCEND programme in type 2 diabetes and chronic kidney disease followed; the first phase 3 readout (TRANSCEND-T2D-1) was published in The Lancet in 2026, and the 80-week TRIUMPH-1 (obesity without diabetes) and TRIUMPH-2 (obesity with type 2 diabetes) trials were published in September 2026, reporting larger mean weight reductions than placebo with predominantly gastrointestinal adverse events. As of October 2026 the compound was not an approved medicine in any jurisdiction.
- Estudios
- 23
- Desde 2023
- 21
- Más reciente
- 2026
- MetabólicoFármaco aprobado
Tesamorelin
Tesamorelin (TH9507) is a synthetic analogue of human growth hormone-releasing hormone (GHRH) that stimulates endogenous, pulsatile growth hormone secretion via the GHRH receptor. It was evaluated in large multicentre phase 3 trials in people with HIV and excess abdominal fat, where visceral adipose tissue was the primary endpoint, and was subsequently approved for HIV-associated lipodystrophy. Later investigator-initiated trials extended the work to hepatic fat in NAFLD/MASLD, to neurocognitive endpoints in mild cognitive impairment and in HIV, and to lean mass and physical function. Recent literature is dominated by meta-analyses of the HIV lipodystrophy trials, MASLD reviews, and preclinical GHRH-agonist neurobiology.
- Estudios
- 34
- Desde 2023
- 13
- Más reciente
- 2026
- MetabólicoFármaco aprobado
Tirzepatide
Tirzepatide (LY3298176) is a fatty acid-modified synthetic peptide that agonises both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors from a single molecule. Receptor pharmacology published between 2018 and 2020 characterised it as imbalanced towards the GIP receptor and biased at the GLP-1 receptor, and rodent work linked that profile to reduced food intake and body weight. Clinical development proceeded through a phase 2 trial against dulaglutide, the SURPASS glycaemic-control programme in type 2 diabetes and the SURMOUNT body-weight programme in obesity, followed by dedicated trials in obstructive sleep apnoea, metabolic dysfunction-associated steatohepatitis and heart failure with preserved ejection fraction. SURPASS-CVOT, an active-comparator cardiovascular outcomes trial in more than 13,000 patients, reported in 2025. Tirzepatide is an approved prescription medicine for type 2 diabetes and for weight management in several jurisdictions, and gastrointestinal adverse events dominate the tolerability profile reported across the programme.
- Estudios
- 43
- Desde 2023
- 29
- Más reciente
- 2026
Investigación publicada más reciente
Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation
Trends in Pharmacological Sciences · revisión de farmacología de inhibidores de NNMT, química medicinal y perspectivas traslacionales
PubMed · 42067476Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis
Cartilage · revisión narrativa de péptidos condroinductivos en modelos de osteoartritis in vitro y animales (en línea primero septiembre 2024; asignado a un número de 2026)
PubMed · 39291443Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Sports Medicine · revisión narrativa que contrasta péptidos aprobados y no aprobados en medicina deportiva, AOD9604 entre ellos
PubMed · 41966639The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Frontiers in Endocrinology · revisión narrativa de péptidos del eje GH-IGF1 incluidos análogos de GHRH, secretagogos y fragmentos de hGH
PubMed · 42395176Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Journal of the American Academy of Orthopaedic Surgeons: Global Research and Reviews · revisión narrativa de péptidos utilizados en el manejo de lesiones ortopédicas
PubMed · 41490200Dermal Necrosis and Chronic Abscess Formation Following Fat Dissolving Injections Administered by a Non-Medical Practitioner: A Case Report
· preprint, not peer reviewed; single case, 33-year-old woman given injections of a lipolytic product purported to be 'Lemon Bottle' into the abdomen and thighs by a non-medical practitioner
Ver fuenteExtracellular phosphatidylcholine functions as a noncanonical TLR4 activator to drive adipocyte lipolysis and apoptosis
Frontiers in Pharmacology · 3T3-L1 adipocytes exposed to phosphatidylcholine at 0-25 mg/mL
PubMed · 42137329Heterotopic ossification of the masseter muscle following injection lipolysis: A case report and review
Journal of Cranio-Maxillo-Facial Surgery · single case report, 35-year-old woman after jawline injection lipolysis
PubMed · 42242003
Solo para fines de investigación. No apto para consumo humano, diagnóstico, tratamiento o prevención de ninguna condición. Nada en esta página constituye consejo médico.